IRIS
TROIANO, Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.150
AS - Asia 8.556
EU - Europa 5.687
SA - Sud America 2.384
AF - Africa 372
Continente sconosciuto - Info sul continente non disponibili 29
OC - Oceania 26
Totale 44.204
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.874
SG - Singapore 3.696
CN - Cina 2.174
BR - Brasile 2.039
HK - Hong Kong 1.248
SE - Svezia 1.199
RU - Federazione Russa 988
IT - Italia 756
DE - Germania 594
VN - Vietnam 562
GB - Regno Unito 515
UA - Ucraina 489
FI - Finlandia 445
CI - Costa d'Avorio 201
FR - Francia 193
IN - India 157
AR - Argentina 147
CA - Canada 145
BD - Bangladesh 111
ID - Indonesia 105
JP - Giappone 94
NL - Olanda 78
BE - Belgio 77
MX - Messico 74
IQ - Iraq 64
ZA - Sudafrica 60
AT - Austria 58
EC - Ecuador 58
TR - Turchia 58
ES - Italia 57
PL - Polonia 56
IR - Iran 51
IE - Irlanda 45
SA - Arabia Saudita 40
CO - Colombia 35
LT - Lituania 34
PK - Pakistan 32
VE - Venezuela 30
EU - Europa 24
PY - Paraguay 24
EG - Egitto 21
UZ - Uzbekistan 21
AU - Australia 20
CL - Cile 17
CZ - Repubblica Ceca 17
IL - Israele 17
JO - Giordania 17
MA - Marocco 17
PE - Perù 17
KE - Kenya 16
TN - Tunisia 15
AE - Emirati Arabi Uniti 13
BG - Bulgaria 11
JM - Giamaica 11
RO - Romania 11
UY - Uruguay 11
AZ - Azerbaigian 10
KZ - Kazakistan 10
TT - Trinidad e Tobago 10
DO - Repubblica Dominicana 9
GR - Grecia 9
OM - Oman 9
PT - Portogallo 9
MY - Malesia 8
NP - Nepal 8
AL - Albania 7
DZ - Algeria 7
KR - Corea 7
SN - Senegal 7
BB - Barbados 6
CH - Svizzera 6
EE - Estonia 6
LB - Libano 6
NZ - Nuova Zelanda 6
PA - Panama 6
PS - Palestinian Territory 6
BO - Bolivia 5
CR - Costa Rica 5
KG - Kirghizistan 5
DK - Danimarca 4
ET - Etiopia 4
GE - Georgia 4
AO - Angola 3
BH - Bahrain 3
HR - Croazia 3
HU - Ungheria 3
KW - Kuwait 3
LK - Sri Lanka 3
LV - Lettonia 3
NG - Nigeria 3
QA - Qatar 3
RS - Serbia 3
A1 - Anonimo 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
CY - Cipro 2
GT - Guatemala 2
HN - Honduras 2
LY - Libia 2
Totale 44.164
Salva come PNG Salva come JPEG
Città #
Fairfield 3.851
Woodbridge 2.754
Ashburn 2.507
Houston 1.832
Chandler 1.816
Singapore 1.802
Seattle 1.530
Cambridge 1.299
Hong Kong 1.248
Wilmington 1.198
Jacksonville 1.162
Ann Arbor 1.141
Nyköping 895
Dallas 834
Beijing 614
Lawrence 448
Roxbury 432
Nanjing 381
Des Moines 299
Los Angeles 296
New York 293
Boardman 268
Princeton 238
Bari 228
Abidjan 201
San Diego 171
São Paulo 170
Ho Chi Minh City 165
Brooklyn 152
Inglewood 148
Buffalo 131
Santa Clara 129
Munich 120
London 116
Hanoi 100
Shenyang 93
Hebei 91
Tokyo 88
Chicago 86
Norwalk 86
Dong Ket 85
Nanchang 85
Moscow 79
Rio de Janeiro 79
Nuremberg 78
Dearborn 75
Helsinki 75
Jakarta 74
Jiaxing 72
Brussels 71
Guangzhou 67
Tianjin 67
Paris 65
North Bergen 52
Frankfurt am Main 51
Toronto 49
Changsha 48
Columbus 46
Belo Horizonte 45
Orem 44
Montreal 43
Warsaw 42
Council Bluffs 41
Dublin 41
Johannesburg 41
San Francisco 41
Shanghai 40
The Dalles 40
Atlanta 39
Amsterdam 36
San Jose 35
Stockholm 35
Washington 35
Dhaka 34
Pune 34
Salt Lake City 33
Denver 30
Rome 30
Wuhan 30
Brasília 29
Marseille 28
Phoenix 28
Chennai 27
Curitiba 27
Poplar 27
Milan 25
Vienna 24
Boston 23
Da Nang 23
Falls Church 23
Mottola 22
Porto Alegre 22
Quito 22
Manchester 21
Salvador 21
Zhengzhou 21
Baghdad 20
Campinas 20
Ribeirão Preto 20
San Mateo 20
Totale 31.913
Salva come PNG Salva come JPEG
Nome #
Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study 313
The role of sexual dysfunction and attachment style in migraine related quality of life 217
A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis 213
Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study 205
Correction to: Disability assessment using Google Maps (Neurological Sciences, (2022), 43, 2, (1007-1014), 10.1007/s10072-021-05389-7) 199
Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. 196
A pattern of cognitive deficits stratified for genetic and environmental risk reliably classifies patients with schizophrenia from healthy control subjects 192
Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis 190
AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding 189
Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport 186
Signs and symptoms of COVID-19 in patients with multiple sclerosis 184
Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice 183
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 182
Assessing response to interferon-β in a multicenter dataset of patients with MS 178
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? 175
DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient 173
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 172
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 172
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 170
Autophagy markers LC3 and p62 accumulate in immune‐mediated necrotizing myopathy 170
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 168
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 165
A rare case of multiple sclerosis and McArdle disease 162
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 162
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes 162
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 161
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. 161
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 161
Prognostic indicators in pediatric clinically isolated syndrome 159
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 156
Investigating the role of microRNA and transcription factor co-regulatory networks in multiple sclerosis pathogenesis 155
A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis 152
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 152
Age-related disability in multiple sclerosis 149
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 149
Age-related changes of serum N-acetyl-aspartate in healthy controls. 148
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 148
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview 148
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 146
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients 146
The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis 146
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 146
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2 143
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 143
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 140
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment 139
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 139
Development of an aquaporin-4 orthogonal array of particle-based ELISA for neuromyelitis optica autoantibodies detection 139
Glatiramer Acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from Multiple Sclerosis patients 138
A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy 137
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 137
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of Multiple Sclerosis 136
Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies 136
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 135
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis 134
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 133
Comparative efficacy of switching to natalizumab in active multiple sclerosis 133
A systematic review of the incidence and prevalence of cancer in multiple sclerosis 133
A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis 133
Caregiver quality of life in multiple sclerosis: a multicentre Italian study 132
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS 132
Multiple sclerosis registries in Europe – An updated mapping survey 132
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 131
Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers 131
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. 130
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis 130
The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review 129
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 129
Risk knowledge in relapsing multiple sclerosis (RIKNO 1.0) - Development of an outcome instrument for educational interventions 129
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 128
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. 127
Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity. 125
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI 124
Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis 123
Apolipoprotein E genotype does not influence the progression of multiple sclerosis 123
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. 123
Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. 122
Treatment decisions in multiple sclerosis-insights from real-world observational studies 122
Psychosocial issue in children and adolescents with multiple sclerosis 121
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 120
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care 120
Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study 119
Treating multiple sclerosis with natalizumab. 119
Epoch analysis of on-treatment disability progression events over time in the Tysabri Observational Program (TOP) 119
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 119
Tissue distribution of the readthrough isoform of AQP4 reveals a dual role of AQP4ex limited to CNS 119
A genome screen for multiple sclerosis in Italian families. 118
Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation 117
Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies 117
Natalizumab discontinuation and disease restart in pregnancy: A case series 117
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient. 116
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 116
Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis 116
Development and validation of the ID-EC - The ITALIAN version of the identify chronic migraine 116
Epstein-Barr virus (EBV) and multiple sclerosis association: EBV has a primary or secondary role? 115
Atypical forms of Multiple Sclerosis or different phases of a same disease? 115
Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study 114
C'era una volta la Didattica...e adesso? 114
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis 114
Defining secondary progressive multiple sclerosis 114
Totale 14.586
Salva come PNG Salva come JPEG
Categoria #
all - tutte 199.246
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 199.246
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.106 0 0 0 0 0 369 513 403 426 655 418 322
2021/20223.282 235 422 48 80 144 289 174 172 237 210 532 739
2022/20234.809 779 506 297 427 616 590 66 558 714 30 126 100
2023/20241.647 153 312 108 110 144 354 60 59 30 63 29 225
2024/20257.632 321 145 641 302 238 631 586 638 373 423 1.102 2.232
2025/20268.792 2.257 776 1.514 1.799 1.654 792 0 0 0 0 0 0
Totale 45.751